XORTX Therapeutics Inc. (XRTX) Earnings History
Annual and quarterly earnings data from 2014 to 2025
Loading earnings history...
XRTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
XRTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export XRTX earnings history in CSV or JSON format
Free sign-in required to download data
XORTX Therapeutics Inc. (XRTX) Earnings Overview
As of May 8, 2026, XORTX Therapeutics Inc. (XRTX) reported trailing twelve-month net income of -$3M, reflecting +50.6% year-over-year growth. The company earned $-10.98 per diluted share over the past four quarters.
Looking at the long-term picture, XRTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$36,922 in fiscal 2014.
XORTX Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARDX (-$58M net income, -15.1% margin), CPRX ($214M net income, 36.4% margin), KRYS ($225M net income, 52.6% margin), XRTX has comparable earnings metrics. Compare XRTX vs ARDX →
XRTX Earnings vs Peers
Earnings metrics vs comparable public companies
XRTX Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$4M | +18.2% | -$5M | $-19.50 | - | - |
| 2024 | -$5M | -58.7% | -$6M | $-39.50 | - | - |
| 2023 | -$3M | +59.1% | -$5M | $-36.00 | - | - |
| 2022 | -$7M | -323.0% | -$12M | $-118.00 | - | - |
| 2021 | -$2M | -28.6% | -$3M | $-30.00 | - | - |
| 2020 | -$1M | -104.0% | -$1M | $-43.25 | - | - |
| 2019 | $-629,576 | +83.3% | $-565,965 | $-25.25 | - | - |
| 2018 | -$4M | -696.3% | -$1M | $-150.75 | - | - |
| 2017 | $-474,201 | -14.3% | $-427,107 | $-55.75 | - | - |
| 2016 | $-414,834 | -48.5% | $-389,315 | $-58.00 | - | - |
See XRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XRTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XRTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXRTX — Frequently Asked Questions
Quick answers to the most common questions about buying XRTX stock.
Is XRTX growing earnings?
XRTX EPS is $-10.98, with earnings growth accelerating to +50.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-3M.
What are XRTX's profit margins?
XORTX Therapeutics Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are XRTX's earnings?
XRTX earnings data spans 2014-2025. The accelerating earnings trend is +50.6% YoY. Historical data enables comparison across business cycles.